Bardet - Biedl syndrome
- characterised by retinal dystrophy, hypogonadism, reduced IQ, obesity (+/- polydactyly) plus renal abnormalities (calcyceal cysts or diverticula, calyceal blunting or clubbing, fetal lobulation)
- this syndrome does not have neurological symptoms (spastic paraplegia) - this differentiates it from Laurence-Moon-Biedl syndrome
- recessive inheritance
- genetic locus:
- BBS1 has no linkage to chromosome 16
- BBS2 is mapped to markers on chromosome 16.
- genetic locus:
- epidemiology
- incidence 1: 160,000; in Newfoundland the incidence is much higher at 1: 16,000
NICE guidance setmelanotide in Bardet-Biedel syndrome
- recommends setmelanotide as an option for treating obesity and hyperphagia in genetically confirmed BBS in people aged ≥ 6 years, only if they are aged between 6 and 17 years when treatment starts
- can carry on having setmelanotide as adults until they need to stop
Main contributor for Bardet - Biedl syndrome section: Thomas Waterfield (October 2007).
Reference:
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.